SANTA CLARA, Calif. / May 22, 2023 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced that the company will participate in Q&A sessions at the Jefferies and Goldman Sachs healthcare conferences. Below are details of each session.
Jefferies Global Healthcare Conference
Mike McMullen, Agilent President and CEO
Wednesday, June 7
9:00 – 9:25 a.m. ET / 6:00 – 6:25 a.m. PT
Goldman Sachs 44th Annual Global Healthcare Conference
Bob McMahon, Agilent CFO
Tuesday, June 13
1:00 – 1:40 p.m. ET / 10:00 – 10:40 a.m. PT
Those interested in listening to the live or recorded sessions can access them from the Events section of Agilent’s investor relations website. Recordings will be available for 90 days.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insight and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
| Last Trade: | US$121.01 |
| Daily Change: | 1.76 1.48 |
| Daily Volume: | 1,759,522 |
| Market Cap: | US$34.370B |
May 27, 2025 April 24, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
